Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.

Ducore, J; Lawrence, J B; Simpson, M; Boggio, L; Bellon, A; Burggraaf, J; Stevens, J; Moerland, M; Frieling, J; Reijers, J; Wang, M

Ducore, J; Lawrence, J B; Simpson, M; Boggio, L; Bellon, A; Burggraaf, J; Stevens, J; Moerland, M; Frieling, J; Reijers, J; Wang, M.

Affiliation

Ducore J; University of California, Davis Health System, Sacramento, CA, USA.
Lawrence JB; LFB USA, Framingham, MA, USA.
Simpson M; Rush University Medical Center, Chicago, IL, USA.
Boggio L; Rush University Medical Center, Chicago, IL, USA.
Bellon A; LFB SA, Paris, France.
Burggraaf J; Centre for Human Drug Research, Leiden, The Netherlands.
Stevens J; Centre for Human Drug Research, Leiden, The Netherlands.
Moerland M; Centre for Human Drug Research, Leiden, The Netherlands.
Frieling J; LFB SA, Paris, France.
Reijers J; Centre for Human Drug Research, Leiden, The Netherlands.
Wang M; Hemophilia & Thrombosis Center, University of Colorado, Aurora, CO, USA.

Haemophilia ; 23(6): 844-851, 2017 Nov.

Article in En | MEDLINE | ID: mdl-28984010

Subject(s)
Key words

Phase Ib; bypassing agents; eptacog beta; inhibitors; recombinant activated factor VII; rhFVIIa

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Proteins / Factor VIIa / Hemophilia B / Hemophilia A Type of study: Prognostic_studies Limits: Adult / Humans / Male / Middle aged Language: En Journal: Haemophilia Journal subject: HEMATOLOGIA Year: 2017 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google